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Introduction
Pompe disease (OMIM #232300) or glycogen storage
disease type II is an autosomal recessive lysosomal sto-
rage disease caused by mutations in the glucosidase
alpha acid (GAA) gene. The acid alpha-glucosidase
enzyme is required for the degradation of cellular glyco-
gen, and its reduced activity results in accumulation of
glycogen in muscle and cardiac tissues with variable
clinical presentation. Demonstration of deficient acid
alpha-glucosidase (GAA) enzyme activity is diagnostic,
and molecular testing is available for confirmation or
clarification. As Pompe disease is in the differential diag-
nosis of a wide variety of myopathies, simple first-line
tests are needed. Use of dried blood spots (DBS) has
logistical advantages over the traditional approach of
enzyme assay in isolated lymphocytes, and enzyme stabi-
lity permits DBS shipment to a central laboratory.
Methods/results
Patients were referred for enzyme testing who presented
with muscle weakness, muscle pain, respiratory insuffi-
ciency, and/or cardiomyopathy in infancy. Dried blood
spot (DBS) acid a-glucosidase testing, with neutral a-
glucosidase as a control enzyme, was measured using a
previously described fluorimetric method [1,2]. Out of
149 samples tested, three cases of Pompe disease were
detected by DBS assay during a three year period. Two
patients with low values for acid a-glucosidase in DBS
were confirmed to carry hypomorphic alleles not asso-
ciated with clinical disease. Two patients with low
values, overlapping those of the two patients with hypo-
morphic alleles, had no mutations detected. Two further
patients had normal results on a second DBS card,
suggesting that the initial blood spots might have been
compromised.
Conclusion
Since the introduction of the DBS alpha-glucosidase
method, several new Pompe cases have been diagnosed
at our centre. A repeat DBS should be requested to con-
firm initial low results before proceeding to further test-
ing. In a significant proportion of false positive cases,
benign hypomorphic alleles provide an explanation for
reduced activity of acid a-glucosidase.
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